(Reuters) - Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.
Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.
Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.
(Reporting by Shailesh Kuber; Editing by Viraj Nair)
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.
- Get Livefyre
- FAQ
